--- title: Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer nct_id: NCT06851442 overall_status: TERMINATED phase: PHASE1, PHASE2 sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. study_type: INTERVENTIONAL primary_condition: Breast Cancer countries: China canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06851442.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06851442" ct_last_update_post_date: 2025-12-12 last_seen_at: "2026-05-12T07:03:27.684Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer **Official Title:** A Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of TQB3912 Tablets in Combination With Fulvestrant Injection± TQB3616 Capsules in Patients With Locally Advanced or Metastatic HR-positive and HER2-negative Breast Cancer. **NCT ID:** [NCT06851442](https://clinicaltrials.gov/study/NCT06851442) ## Key Facts - **Status:** TERMINATED - **Why Stopped:** This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns. - **Phase:** PHASE1, PHASE2 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 8 - **Lead Sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd. - **Conditions:** Breast Cancer - **Start Date:** 2025-05-16 - **Completion Date:** 2025-11-20 - **CT.gov Last Update:** 2025-12-12 ## Brief Summary This trial was designed to evaluate the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) in subjects with TQB3912 tablets combined with fulvestrant injection and TQB3616 capsules for locally advanced or metastatic HR-positive and HER2-negative breast cancer.And the effectiveness of TQB3912 tablets combined with fulvestrant injection ±TQB3616 capsules in locally advanced or metastatic HR-positive and HER2-negative breast cancer subjects was evaluated by evaluating ORR, PFS, DOR, DCR, CBR, OS, etc., and at the same time, Assess its safety and pharmacokinetic (PK) characteristics. ## Eligibility - **Minimum age:** 18 Years - **Maximum age:** 75 Years - **Sex:** ALL - **Healthy Volunteers:** No ``` Inclusion Criteria: * The subjects voluntarily joined the study, signed an informed consent form, and had good compliance. * Age: 18-75 years old; Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score: 0\~1 point; estimated survival time exceeds 3 months. * Women can be in the late period of menopause and before menopause/innerspring. If they are before menopause/siege period, they must continue to receive ovarian function inhibitory treatment during the research period to enter the group. * Anthropologically confirmed HR-positive and HER2-negative breast cancer. * Locally advanced or metastatic diseases that cannot undergo radical surgery. * Queue 1 Previous treatment requirements: progress after endocrine therapy; Queue 2 Previous treatment requirements: progress after endocrine therapy. * Have one or more phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)/v-akt murine thymoma viral oncogene homolog 1 (AKT1)/phosphatase and tensin homolog deleted on chromosome ten (PTEN) gene mutations. * At least one measurable lesion exists according to the RECIST 1.1 standard. * Good function of the main organs * Female subjects of childbearing age should agree that contraceptive measures (such as Buds, contraceptives or condoms) must be used during the study period and within 6 months after the study ends; the serum pregnancy test is negative within 7 days before the study enrollment. , and must be non-lactation subjects; male subjects should agree to adopt contraceptive measures within 6 months after the end of the study period. Exclusion Criteria: * It is known to suffer from spinal cord compression, cancerous meningitis, symptoms with brain metastasis or symptoms control for less than 4 weeks. * Combined diseases and medical history: 1. Have appeared within 3 years or have also suffered from other malignant tumors; 2. Adverse reactions from previous treatments have not been restored to CTCAE 5.0 grade≤1; 3. It affects oral and drug absorption 4. Those who have received major surgical treatment within 4 weeks before the first medication, obvious traumatic injury or expected to undergo major surgery during the study treatment, or have long-term uncured wounds or fractures; 5. Congenital bleeding , coagulation dysfunction disease; 6. Arterial/deep thrombosis events occurred; 7. Blood pressure control was not ideal; 8. Major cardiovascular disease; 9. Uncontrolled ≥CTCAE level 2 within 14 days before the start of study treatment 10. A history of active tuberculosis, pulmonary fibrosis or pneumonia; 11. a past or currently associated with interstitial lung disease/pneumonia; 12. active viral hepatitis and poor control; 13. treatment is required 14. uncontrollable kidney disease; 15. a history of immunodeficiency; 16. a person who is prepared to undergo or has undergone genealogical bone marrow transplants or solid organ transplants; 17. uncontrollable diabetes; 18. a person who suffers from People with epilepsy and need treatment; 19. People with a history of psychotropic substance abuse and cannot be abstained or have mental disorders. * Tumor-related symptoms and treatment: 1. If it is not controlled, the third gap effusion still needs to be repeatedly drained; 2. There is lung cancer pharyngitis; 3. During the study period, the tumor is very likely to invade important blood vessels and cause it Fatal severe bleeding; 4. Use strong CYP3A4 inhibitor or strong inducer, and the drug half-life is less than 3 before the start of the study treatment; 5. Have received anti-tumor treatment within 3 weeks before the start of the study treatment, and the washing is calculated from the end of the last treatment 6. Within 2 weeks before the start of the study treatment, Chinese patent medicine treatment with anti-tumor indications was received in the National Medical Products Administration (NMPA) approved drug instructions. * Research and treatment related: 1. Used phosphatidylinositol 3 kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitors; 2. Used fulvestrant or other selective estrogen receptor degrading agents (SERD); 3. Used in any study drug or drug Allergic to any ingredient or excipient; 4. a history of live attenuated vaccination within 28 days before the first medication or planned to undergo live attenuated vaccination during the study period; 5. is receiving systemic glucocorticoid therapy or any other form of immunosuppression therapy, and Continued use within 2 weeks before the start of the study treatment * According to the judgment of the researcher, there are situations that seriously endanger the safety of the subject or affect the subject's completion of the research. ``` ## Arms - **TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules** (EXPERIMENTAL) — TQB3912 tablets 120 mg quaque die (QD), + fulvestrant injection 500 mg quaque 4 week(Q4W) (C1D15),28 days as a treatment cycle. Or TQB3912 tablets 120 mg quaque die(QD)+TQB3616 capsules 80 mg/120 mg QD +fulvestrant injection 500 mg quaque 4 week(Q4W) (C1D15), 28 days as a treatment cycle. ## Interventions - **TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules** (DRUG) — Protein kinase B(AKT) inhibitors+Cyclin-dependent kinase 4/6(CDK4/6) Inhibitor+Estrogen receptor antagonists. ## Primary Outcomes - **Maximum tolerated dose (MTD)** _(time frame: 4 months after Queue 2 begins enrollment)_ — Phase Ib of Queue 2maximum tolerated dose (MTD, if any) - **phase II recommended dose (RP2D)** _(time frame: 4 months after Queue 2 begins enrollment)_ — Phase II Queue 2: phase II recommended dose (RP2D). - **Objective Remission Rate (ORR)** _(time frame: 8 to 16 weeks after enrollment)_ — Cohort 1, Phase II of Cohort 2: Objective Remission Rate (ORR). ## Secondary Outcomes - **Progression-free survival (PFS)** _(time frame: From enrollment to disease progression, an average of 14 months)_ - **Duration of response (DOR)** _(time frame: From enrollment to disease progression, an average of 14 months)_ - **Disease control rate (DCR)** _(time frame: 8 to 16 weeks after enrollment)_ - **Clinical benefit ratio (CBR)** _(time frame: ≥24 weeks after enrollment)_ - **Overall survival (OS)** _(time frame: From enrollment to subject death, it is expected to be evaluated until 5 years)_ - **Number of patients with adverse events (AEs) and serious adverse events (SAEs)** _(time frame: Within 28 days after dosing)_ - **Peak time (Tmax)** _(time frame: Within 24 hours after dosing)_ - **Peak concentration (Cmax)** _(time frame: 30 minuets pre-dose at cycle 1 day 1, 8 and day 28. 30 minuets,1, 2, 3, 4, 6, 8, 12, 24 hours after dose at cycle 1 day 1 and day 28. Each cycle is 28 days)_ - **Elimination half life (t1/2)** _(time frame: Within 1～7 days after dose)_ - **Area under plasma concentration-time curve (AUC0-∞)** _(time frame: Within 28 days after dosing)_ ## Locations (17) - The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China - Fuzhou First General Hospital, Fuzhou, Fujian, China - Quanzhou First Hospital, Quanzhou, Fujian, China - Meizhou peoples Hospital, Meizhou, Guangdong, China - Guizhou Medical University Affiliated Cancer Hospital Co., Ltd, Guiyang, Guizhou, China - Guizhou Provincial People's Hospital, Guiyang, Guizhou, China - Harbin Medical University Cancer, Harbin, Heilongjiang, China - Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China - Yongzhou Central Hospital, Yongzhou, Hunan, China - Liaoning Cancer Hospital, Shenyang, Liaoning, China - The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, Shaanxi, China - Shanxi Cancer Hospital, Taiyuan, Shanxi, China - Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin Municipality, China - Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin Municipality, China - Xinjiang Medical University Affiliated Cancer Hospital, Ürümqi, Xinjiang, China - Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China - Taizhou Central Hospital (Taizhou University Affiliated Hospital), Taizhou, Zhejiang, China ## Recent Field Changes (last 30 days) - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `status.overallStatus` — added _(2026-05-12)_ - `status.whyStopped` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.the first affiliated hospital of bengbu medical college|bengbu|anhui|china` — added _(2026-05-12)_ - `locations.fuzhou first general hospital|fuzhou|fujian|china` — added _(2026-05-12)_ - `locations.quanzhou first hospital|quanzhou|fujian|china` — added _(2026-05-12)_ - `locations.meizhou peoples hospital|meizhou|guangdong|china` — added _(2026-05-12)_ - `locations.guizhou medical university affiliated cancer hospital co., ltd|guiyang|guizhou|china` — added _(2026-05-12)_ - `locations.guizhou provincial people's hospital|guiyang|guizhou|china` — added _(2026-05-12)_ - `locations.harbin medical university cancer|harbin|heilongjiang|china` — added _(2026-05-12)_ - `locations.zhongnan hospital of wuhan university|wuhan|hubei|china` — added _(2026-05-12)_ - `locations.yongzhou central hospital|yongzhou|hunan|china` — added _(2026-05-12)_ - `locations.liaoning cancer hospital|shenyang|liaoning|china` — added _(2026-05-12)_ - `locations.the first affiliated hospital of xi'an jiao tong university|xi'an|shaanxi|china` — added _(2026-05-12)_ - `locations.shanxi cancer hospital|taiyuan|shanxi|china` — added _(2026-05-12)_ - `locations.tianjin cancer hospital airport hospital|tianjin|tianjin municipality|china` — added _(2026-05-12)_ - `locations.tianjin medical university cancer institute & hospital|tianjin|tianjin municipality|china` — added _(2026-05-12)_ - `locations.xinjiang medical university affiliated cancer hospital|ürümqi|xinjiang|china` — added _(2026-05-12)_ - `locations.ningbo medical center lihuili hospital|ningbo|zhejiang|china` — added _(2026-05-12)_ - `locations.taizhou central hospital (taizhou university affiliated hospital)|taizhou|zhejiang|china` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT06851442.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT06851442* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*